№ files_lp_4_process_1_31932
File format: docx Character count: 19853 File size: 62 KB
The document outlines the request for extending the PBS listing for atezolizumab in the treatment of extensive stage small cell lung cancer (ES-SCLC) in Australia, focusing on dosage adjustments and treatment phases.
Year: 2023
Region / city: Australia
Topic: Pharmaceutical application for medication dosage and treatment guidelines
Document type: Application for extension of medical listing
Organization / Institution: Pharmaceutical Benefits Advisory Committee (PBAC), Roche Products Pty Ltd
Author: Roche Products Pty Ltd
Target audience: Medical professionals, Pharmaceutical committee, Healthcare providers
Effective period: Ongoing
Approval date: 2023
Modification date: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
ATEZOLIZUMAB, Solution concentrate for I.V. infusion 840 mg in 14 mL, Solution concentrate for I.V. infusion 1,200 mg in 20 mL, Tecentriq®, Roche Products Pty Ltd
Year: 2023
Region / City: Australia
Theme: Oncology, Lung Cancer
Document Type: Medical Submission
Organization / Institution: Roche Products Pty Ltd
Author: Not specified
Target Audience: Medical professionals, healthcare providers
Period of Validity: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
ATEZOLIZUMAB, solution concentrate for I.V. infusion 1200 mg in 20 mL, solution concentrate for I.V. infusion 840 mg in 14 mL, Tecentriq® plus BEVACIZUMAB, solution for I.V. infusion 100 mg in 4 mL, solution for I.V. infusion 400 mg in 16 mL, Avastin®, Roche Products Pty Ltd
Year: 2020
Region / city: Australia
Topic: Cancer Treatment, Pharmacology
Document type: Submission for Pharmaceutical Listing
Organization / institution: Roche Products Pty Ltd
Author: Unknown
Target audience: Pharmaceutical regulators, healthcare professionals
Validity period: Ongoing review process
Approval date: 2020-01-10
Amendment date: Not specified
Topics: mg14 ES-SCLC ATEZOLIZUMAB